Biosimilars 2020 Year in Review
Fish & Richardson Trademark & Copyright Thoughts
FEBRUARY 4, 2021
The parties are currently engaged in supplemental expert discovery on Hospira and Pfizer’s on-sale bar and public use defenses, and the court has resolved two discovery disputes this year stemming from these issues. For example, evidence was submitted that Hospira was not required by FDA to manufacture additional batches after 2012.
52 
Let's personalize your content